Key result
A HAS-BLED score of ≥3 points identified patients with acute venous thromboembolism at an 8.7-fold increased risk of major bleeding complications during the first 6 months of VKA treatment.
Why the study?
Does a HAS-BLED score ≥ 3 identify patients at high risk of major bleeding during vitamin K-antagonist treatment for acute venous thromboembolism?
Population
537 patients with acute venous thromboembolism starting vitamin K-antagonist treatment between 2006-2007
Comparison
High HAS-BLED score (≥ 3 points) vs Non-high HAS-BLED score (< 3 points)
Design
Cohort
Follow-up
180 days
Authors
Loading...
HAS-BLED ≥3 identifies higher major bleed risk in acute VTE on VKA; supports extension to this population but leaves validation open.
Cohort (n=537)
Yes
Does a HAS-BLED score ≥ 3 identify patients at high risk of major bleeding during vitamin K-antagonist treatment for acute venous thromboembolism?
Hazard Ratio: 8.7 (95% CI 2.7–28.4)
Absolute Event Rate: 9.6% vs 1.3%
p-value: p=<0.0001
The HAS-BLED score, originally designed for atrial fibrillation, effectively identifies acute VTE patients at high risk for major bleeding during the first 6 months of vitamin K-antagonist therapy.
Kooiman et al. (2015) conducted a cohort in Acute venous thromboembolism (VTE) (n=537). HAS-BLED score ≥ 3 (high risk) vs. HAS-BLED score < 3 (non-high risk) was evaluated on Occurrence of major bleeding events (HR 8.7, 95% CI 2.7-28.4, p=<0.0001). A HAS-BLED score of ≥3 points identified patients with acute venous thromboembolism at an 8.7-fold increased risk of major bleeding complications during the first 6 months of VKA treatment.